Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial

Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial

Summary: Background: The 2013–15 Ebola virus disease epidemic in west Africa greatly accelerated the development of Ebola vaccine. We aimed to analyse the immune persistence induced by one shot of an adenovirus type-5 vector-based Ebola virus vaccine up to 6 months and the effect of boosting with a...

Full description

Bibliographic Details
Main Authors: Jing-Xin Li, PhD, Li-Hua Hou, PhD, Fan-Yue Meng, MSc, Shi-Po Wu, PhD, Yue-Mei Hu, BS, Qi Liang, BS, Kai Chu, MSc, Zhe Zhang, BS, Jun-Jie Xu, PhD, Rong Tang, MSc, Wen-Juan Wang, MSc, Pei Liu, ProfPhD, Jia-Lei Hu, MSc, Li Luo, MSc, Rong Jiang, MSc, Feng-Cai Zhu, MSc, Wei Chen, PhD
Format: Article
Language:English
Published: Elsevier 2017-03-01
Series:The Lancet Global Health
Online Access:http://www.sciencedirect.com/science/article/pii/S2214109X16303679

Internet

http://www.sciencedirect.com/science/article/pii/S2214109X16303679

Similar Items